Exam 4 Material Flashcards
FTU scalp
3
FTU face and neck
2.5
FTU One hand (front and back) including fingers
1
FTU One arm including entire hand
4
FTU elbows
1
FTU both soles
1.5
FTU one foot including toes
2
FTU one leg including foot
8
FTU buttocks
4
FTU knees
1
FTU trunk both sides
14 (7 FTU each side)
scaly dermatoses
dandruff
seborrheic dermatitis
location of dandruff
scalp
exacerbating factors of dandruff
generally stable; increases in dry climate, cold temperature, or stress
appearance of dandruff
thin, white, or grey flakes on scalp
inflammation of dandruff
absent
epidermal hyperplasia of dandruff
absent
epidermal kinetics of dandruff
2x’s faster than normal
location of seborrheic dermatitis
scalp, face, and trunk
exacerbating factors of seborrheic dermatitis
immunosuppression, neurologic conditions, environmental factors, stress
appearance of seborrheic dermatitis
macules, patches and thin plaques of discrete yellow, oily scales on red skin
inflammation of seborrheic dermatitis
present
epidermal hyperplasia of seborrheic dermatitis
present
epidermal kinetics of seborrheic dermatitis
3x’s faster than normal
location of psoriasis
scalp, elbows, knees, trunk, lower extremities
exacerbating factors of psoriasis
environmental factors, infection, medications, stress, alcohol, tobacco
appearance of psoriasis
discrete symmetrical, red plaques with sharp borders; silvery white scales, bleeding points
inflammation of psoriasis
present
epidermal hyperplasia of psoriasis
present
epidermal kinetics of psoriasis
8x’s faster than normal
dandruff
chronic and non-inflammatory hyperproliferative epidermal scalp condition
-accelerated epidermal cell turnover and abnormal keratinization
-presence of Malassezia fungi
-causes mild inflammation, flaking, and pruritus
treatment goals of dandruff
reduce epidermal turnover rate of scalp skin and reduce the # of Malassezia fungi
minimize the cosmetic embarrassment of visible scarring
minimize itching
general treatment approach of mild dandruff
non-medicated shampoo: daily or every other day
mild presentation of dandruff
intermittent dandruff, mild inflammation
general treatment approach of moderate-severe dandruff
OTC medicated shampoos (pyrithione zinc, selenium sulfide, coal tar)
-leave on scalp for 3-5 min
-rinse well with water
-daily for 1 week, then 2-3 times weekly for 2-3 weeks, then once a week
moderate-severe presentation of dandruff
daily dandruff
moderate-severe inflammation
seborrheic dermatitis
chronic inflammatory disorder in areas of sebaceous gland activity (face, scalp, and chest)
involves Malassezia species and accelerated epidermal proliferation
no specific cure
neither harmful nor contagious
affects infants, adolescents, and adults
presentation of seborrheic dermatitis in infants
greasy or dry scaling of the scalp
aka cradle cap
presentation of seborrheic dermatitis in adolescents/adults
yellow, greasy scales in patches or plaques with exudates and crusting on red inflamed skin
-head, ear, face
-chest, mid-upper trunk and gluteal crease
-intertriginous areas
persons with darker pigmentation may present with hypopigmentation
increased risk and triggers seborrheic dermatitis
Malassezia
physical stress, fatigue, travel
zinc deficiency
change of season-worsens in cold weather
HIV infection; AIDS
Parkinson’s disease
treatment goals of seborrheic dermatitis
reduce inflammation and epidermal turnover rate
minimize or eliminate visible erythema and scaling
general treatment approach of seborrheic dermatitis
loosen and remove scales and crusts
inhibit yeast colonization (Malassezia)
reduce erythema and itching
avoid perfumes, aftershave, ointments, soaps
control secondary infections
seborrheic dermatitis can be softened with
mineral oil or olive oil
cream containing salicylic acid or sulfur
seborrheic dermatitis skin should be washed _________ than 2x daily
more; may use dishwashing liquid
decreasing fungal growth for seborrheic dermatitis
wash the scalp with OTC antifungal shampoo
face and body: topical treatment with antifungal creams
UV light therapy
wash the scalp with OTC antifungal shampoo for seborrheic dermatitis
ketoconazole (1st line) or selenium sulfide, pyrithione zinc, cicpirox, coal tar (2nd lines)
-leave on scalp for 3-5 min
-daily for 1-2 weeks
-2-3 times a week for 4 weeks
-if see improvement after 4 weeks, may reduce the frequency to once weekly
-if disorder worsens or symptoms persist longer than 7 days, a health care provider should be consulted
OTC antifungal shampoo first line
ketoconazole
OTC antifungal shampoo 2nd line
selenium sulfide, pyrithione zinc, cicopirox, coal tar
how long should you wait to consult a health care provider regarding seborrheic dermatitis
if disorder worsens or symptoms persist > 7 days
reduce erythema and itching of seborrheic dermatitis
corticosteroid lotion for scalp
corticosteroid cream for other parts of the body
use moisturizing emollients after washing
ketoconazole shampoo and corticosteroid lotion most often are combined in therapy resistant cases
ketoconazole shampoo and corticosteroid lotion are combined together for
therapy resistant cases of seborrheic dermatitis
seborrheic dermatitis treatment in infant’s scalp
massage scalp with baby oil or vegetable oil
then shampoo with non-medicated shampoo
use soft bristled brush
for severe cases salicylic acid 3-5% in olive oil or water-soluble base
seborrheic dermatitis treatment in infant’s face
wash with mild soap or cleanser, apply facial emollient
DO NOT suggest corticosteroids
psoriasis
common chronic inflammatory disease
involves adaptive and innate immunity
T cell mediated inflammatory
predisposing and precipitating factors of psoriasis
multiple genetic factors
injury to the skin
a viral or strep skin infection
alcohol consumption
smoking cigarettes
obesity/metabolic syndrome
stress
medications
predisposing and precipitating medications for psoriasis
lithium
NSAIDs
antimalarials
B blockers
fluoxetine
withdrawal of corticosteroids
possible comorbidities of psoriasis
psoriatic arthritis
CV diseases
-MI
-stroke
-peripheral vascular disease
metabolic syndrome
malignancy
-T cell lymphoma
inflammatory bowel diseases
-Crohn’s
-ulcerative colitis
psychological illness
-anxiety
-depression
renal disease
treatment factors for psoriasis
age/sex
socio-economic status
comorbidities
past/current treatment
location of lesions
severity of disease
mild psoriasis
BSA < 5%
moderate psoriasis
BSA >8%
severe psoriasis
BSA > 10%
lifestyle recommendations for psoriasis
reduce stress
regular exercise
weight management
moderation of alcohol
cessation of smoking
non-pharm treatments of psoriasis
moisturizers/emollients
oatmeal baths
sunscreen
pharm therapies for mild to moderate psoriasis
topical agents->topical agents + phototherapy->topical agents + systemic agent
+ nonpharm
topical agents of psoriasis (mild-moderate)
corticosteroids
vitamin D3 analogue
retinoids
anthralin
coal tar
salcylic acid
calcineurin inhibitor-pimecrolimus
corticosteroids for psoriasis
apply 2-4 times daily: cream or lotion-day, ointment-night
low potency for face, skin fold. limit duration and SA
vitamin D3 analogue (calcipotriene) for psoriasis
apply once or twice daily (ointment); twice daily (cream or foam)
retinoids for psoriasis
tazarotene, adapalene
apply once daily at bedtime
anthralin for psoriasis
applied only to the thick plaque lesions for 2 hrs or less and then wiped off (use Zn oxide around edges to protect normal skin)
SCAT therapy
coal tar for psoriasis
apply in evening, wash off in morning
salicylic acid for psoriasis
shampoo for scalp lesions
calcineurin inhibitors for psoriasis
pimecrolimus
apply to intertriginous areas (skin folds)
treatment for moderate to severe psoriasis
- systemic agent =/- topical agent or phototherapy; consider biologic agent esp if comorbidities exist
- more potent systemic agent or biologic agent (or less commonly 2 or more systemic agents in rotation) +/- topical agent
- biologic agent (if not already used) +/- other agents
+ nonpharm
systemic agent options for psoriasis
apremilast (otezla)
tofacitinib (xeljanz)
acitretin
methotrexate
cyclosporine
abatacept (orencia)
apremilast/otezla
PDE-4 inhibitor
dose titration to max 30 mg BID over 1st week
renal impairment-once daily dosing
should see response by week 4
ADRs-N/V/D, depression, weight loss
tofacitinib/xeljanz
JAK inhibitor
psoriatic arthritis after fail on MTX
immunosuppressive
DO NOT use with DMARDs or with potent immunosuppressants; NO live vaccines
high risk of serious invasive infections
monitor lymphocytes, neutrophils, hemoglobin, liver enzymes, and lipids
BBW: serious cardiac events
what can you not take/use with tofacitinib/xeljanz
biologic DMARDs or with potent immunosuppressants
NO live vaccines
tofacitinib/xeljanz BBW
serious cardiac events such as heart attack or stroke, cancer, blood clots, and death
acitretin for psoriasis
retinoid (oral)
NOT immunosuppressive
max response 3-6 months
DO NOT drink alcohol
reproductive aged women-should not be pregnant or plan to become pregnant within 3 years following drug discontinuation
methotrexate for psoriasis
T cell and cytokine suppressors-oral DMARD
onset of action: 3-6 weeks
administer with folic acid
screen: CBC, LFTs
CI: pregnancy, cirrhosis, blood dyscrasias
increased risk of hepatotoxicity
what should you administer with MTX
folic acid
what are the contraindications of MTX
pregnancy, cirrhosis, blood dyscrasias
cyclosporine for psoriasis
T cell and cytokine suppressors-oral DMARD
not recommended for prolonged use (< 4 months bc of nephrotoxicity
dose on actual body weight
many drug interactions
CI: systemic malignancy, untreated HTN or infections
increased risk for elderly-HTN
what is the longest time frame that you can be on cyclosporine
4 months
contraindications of cyclosporine
systemic malignancy, untreated HTN or infections
abatacept/orencia
blocks T cell activation
SQ injection
screen: TB
interactions: live vaccines, COPD
biologics counseling points
NO live vaccines
screen for TB prior and during therapy (PPD annually)
discontinue therapy during active infection
adverse effects of biologics
increased risk of infections
contraindicated in patients with active infections/sepsis
hypersensitivity rxns
lymphoma and other malignancies
worsening or new onset heart failure: TNFa inhibitors
Biologic agents for psoriasis
adalimumab (humira)
etanercept (enbrel)
infliximab (remicade)
golimumab (simponi)
certolizumab (cimzia)
ustekinumab (stelara)
tildrakizumab (ilumya)
risankizumab (skyriza)
guselkumab (tremfya)
secokinumab (cosentyx)
ixekizumab (taltz)
brodalumab (siliq)
TNFa inhibitors
adalimumab (humira)
etanercept (enbrel)
infliximab (remicade)
golimumab (simponi)
certolizumab (cimzia)
TNFa inhibitors comments
TB testing should be performed on all patients, annually
Hep B screening recommended
monitor: CBC and LFTs
DO NOT use with:
-live vaccines
-patients with or with 1st degree relatives with a demyelinating disease or multiple sclerosis (MS)
-congestive heart failure
who can you not use TNFa inhibitors with
-live vaccines
-patients with or with 1st degree relatives with a demyelinating disease or multiple sclerosis (MS)
-congestive heart failure
ustekinumab/stelara
IL-12 and 23
avoid in ACTIVE TB; do not give concurrently with live vaccines
PPD monitoring
tildrakizumab/ilumya
IL-23
avoid in active TB; no live vaccines
risankizumab
IL-23
avoid in active TB; no live vaccines
guselkumab/tremfya
IL-23
avoid in active TB; no live vaccines
secukinumab/cosentyx
Crohn’s
ixekizumab/taltz
IL-17A
brodalumab/siliq
IL-17A
BBW: increased suicide risk
must complete REMS
safety considerations for use of ALL biologics
serious infections, including TB
malignancies and lymphomas
anaphylaxis
safety considerations for use of anti-TNFs biologics
heart failure worsening
demyelinating disease
Hep B reactivation
cytopenias
lupus-like syndrome
safety considerations for use of anti-ILs biologics
inflammatory bowel disease
depression worsening
photochemotherapy for psoriasis
need skin biopsy of lesion to confirm diagnosis of psoriasis
90% efficacy with oral psoralens + UVA light
reserved for patients with severe, refractory psoriasis
side effects of photochemotherapy for psoriasis
serious burns, blistering, peeling, itching, nausea, potential increase in certain cancer rates (basal/melanoma), photoaging
MOA of photochemotherapy for psoriasis
psoralen cross-links with DNA in presence of UVA light; effects immune response in skin and lymphocytes
integrative and alternative medicine for psoriasis
traditional chinese medicine
herbal therapies
diet/dietary supplements
mind/body therapies
plant contact dermatitis is caused by what
urushiol
urushiol
active irritant, oily liquid
sensitization phase
elicitation phase
sensitization phase of urushiol/plant contact dermatitis
enters skin within 10 min of contact
urushiol binds to epidermal proteins to form an antigen
elicitation phase of urushiol/plant contact dermatitis
upon continued/subsequent exposures, hypersensitivity rxn occurs
rash may appear 2-48 hr after exposure
rash continues for 1-3 weeks
fast onset, long recovery